These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35852488)

  • 1. MHC Class I Enables MSCs to Evade NK-Cell-Mediated Cytotoxicity and Exert Immunosuppressive Activity.
    Oh JY; Kim H; Lee HJ; Lee K; Barreda H; Kim HJ; Shin E; Bae EH; Kaur G; Zhang Y; Kim E; Lee JY; Lee RH
    Stem Cells; 2022 Sep; 40(9):870-882. PubMed ID: 35852488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice.
    Eliopoulos N; Stagg J; Lejeune L; Pommey S; Galipeau J
    Blood; 2005 Dec; 106(13):4057-65. PubMed ID: 16118325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.
    Berglund AK; Schnabel LV
    Equine Vet J; 2017 Jul; 49(4):539-544. PubMed ID: 27862236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.
    Schnabel LV; Pezzanite LM; Antczak DF; Felippe MJ; Fortier LA
    Stem Cell Res Ther; 2014 Jan; 5(1):13. PubMed ID: 24461709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
    Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
    Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.
    Huang XP; Ludke A; Dhingra S; Guo J; Sun Z; Zhang L; Weisel RD; Li RK
    FASEB J; 2016 Sep; 30(9):3069-82. PubMed ID: 27221978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive properties of mesenchymal stem cells: advances and applications.
    De Miguel MP; Fuentes-Julián S; Blázquez-Martínez A; Pascual CY; Aller MA; Arias J; Arnalich-Montiel F
    Curr Mol Med; 2012 Jun; 12(5):574-91. PubMed ID: 22515979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo.
    Isakova IA; Lanclos C; Bruhn J; Kuroda MJ; Baker KC; Krishnappa V; Phinney DG
    PLoS One; 2014; 9(1):e87238. PubMed ID: 24489878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison of the immunogenicity of major histocompatibility complex-I and -II deficient mesenchymal stem cells
    Halm D; Leibig N; Martens J; Stark GB; Groß T; Zimmermann S; Finkenzeller G; Lampert F
    Biol Chem; 2021 May; 402(6):693-702. PubMed ID: 33544464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.
    de la Garza-Rodea AS; Verweij MC; Boersma H; van der Velde-van Dijke I; de Vries AA; Hoeben RC; van Bekkum DW; Wiertz EJ; Knaän-Shanzer S
    PLoS One; 2011 Jan; 6(1):e14493. PubMed ID: 21253016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insensitivity of Human iPS Cells-Derived Mesenchymal Stem Cells to Interferon-γ-induced HLA Expression Potentiates Repair Efficiency of Hind Limb Ischemia in Immune Humanized NOD Scid Gamma Mice.
    Sun YQ; Zhang Y; Li X; Deng MX; Gao WX; Yao Y; Chiu SM; Liang X; Gao F; Chan CW; Tse HF; Shi J; Fu QL; Lian Q
    Stem Cells; 2015 Dec; 33(12):3452-67. PubMed ID: 26175298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients.
    Cui R; Rekasi H; Hepner-Schefczyk M; Fessmann K; Petri RM; Bruderek K; Brandau S; Jäger M; Flohé SB
    Stem Cell Res Ther; 2016 Jul; 7(1):88. PubMed ID: 27388156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Immunomodulatory Effects of Human Bone Marrow-Derived Mesenchymal Stromal Cells on Natural Killer Cells.
    Hu CD; Kosaka Y; Marcus P; Rashedi I; Keating A
    Stem Cells Dev; 2019 Jul; 28(14):933-943. PubMed ID: 31122145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.
    Cequier A; Vázquez FJ; Romero A; Vitoria A; Bernad E; García-Martínez M; Gascón I; Barrachina L; Rodellar C
    Front Vet Sci; 2022; 9():957153. PubMed ID: 36337202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.
    Selmani Z; Naji A; Zidi I; Favier B; Gaiffe E; Obert L; Borg C; Saas P; Tiberghien P; Rouas-Freiss N; Carosella ED; Deschaseaux F
    Stem Cells; 2008 Jan; 26(1):212-22. PubMed ID: 17932417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties.
    Berglund AK; Long JM; Robertson JB; Schnabel LV
    Front Cell Dev Biol; 2021; 9():628382. PubMed ID: 33614658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-induced increase in Sug1 leads to poor post-transplantation survival of allogeneic mesenchymal stem cells.
    Abu-El-Rub E; Sareen N; Lester Sequiera G; Ammar HI; Yan W; ShamsEldeen AM; Rubinchik I; Moudgil M; Shokry HS; Rashed LA; Dhingra S
    FASEB J; 2020 Sep; 34(9):12860-12876. PubMed ID: 32770803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells.
    Crop MJ; Korevaar SS; de Kuiper R; IJzermans JN; van Besouw NM; Baan CC; Weimar W; Hoogduijn MJ
    Cell Transplant; 2011; 20(10):1547-59. PubMed ID: 21396164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility:
    Cequier A; Vázquez FJ; Vitoria A; Bernad E; Fuente S; Serrano MB; Zaragoza MP; Romero A; Rodellar C; Barrachina L
    Front Vet Sci; 2024; 11():1391872. PubMed ID: 38957800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies.
    Hoogduijn MJ; Roemeling-van Rhijn M; Korevaar SS; Engela AU; Weimar W; Baan CC
    Hum Gene Ther; 2011 Dec; 22(12):1587-91. PubMed ID: 21732766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.